publication . Other literature type . Article . 2009

PIB Imaging Predicts Progression from Cognitively Normal to Symptomatic Alzheimer’s Disease

John C. Morris; Catherine M. Roe; Elizabeth A. Grant; Denise Head; Martha Storandt; Alison M. Goate; Anne M. Fagan; David M. Holtzman; Mark A. Mintun;
Open Access English
  • Published: 01 Dec 2009
Objective To determine whether preclinical Alzheimer disease (AD), as detected by the amyloid-imaging agent Pittsburgh Compound B (PiB) in cognitively normal older adults, is associated with risk of symptomatic AD. Design A longitudinal cohort study of cognitively normal older adults assessed with positron emission tomography (PET) to determine the mean cortical binding potential for PiB and followed up with annual clinical and cognitive assessments for progression to very mild dementia of the Alzheimer type (DAT). Setting The Alzheimer's Disease Research Center, Washington University, St Louis, Missouri. Participants One hundred fifty-nine participants with a m...
Medical Subject Headings: mental disorders
free text keywords: Article, Arts and Humanities (miscellaneous), Clinical Neurology, Confidence interval, Pittsburgh compound B, chemistry.chemical_compound, chemistry, Clinical Dementia Rating, Anesthesia, Alzheimer's disease, medicine.disease, medicine, Pathology, medicine.medical_specialty, business.industry, business, Internal medicine, Central nervous system disease, Parahippocampal gyrus, medicine.anatomical_structure, Dementia, Hazard ratio, Oncology
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue